To inquire about our available technologies, call our office (813) 745-6828
| Name & Description | Number |
|---|---|
| ULK3: ULK3 Inhibitors for the Treatment of Multiple Myeloma | 22MA087 |
| Immunomodulatory: Cereblon Degrading Molecules for the Treatment of Small Cell Lung Carcinoma and Melanoma | 22MA084 |
| Small Molecule Inhibitor: 3-(4-fluorophenyl)-N-phenylbenzamide Small-Molecule Inhibitors of the β-Catenin/BCL9 Protein-Protein Interaction | 22MA004N |
| YAP1/OCT4: Small Molecule Inhibitors of the Protein Protein Interaction of YAP1 and OCT4 to Treat Cancer | 21MB072 |
| TAF1: Novel TAF1 PROTACS for the Treatment of Cancer | 21MB065N |
| Antibodies: Novel Targeted Nanobodies Against HPV E6/E7 to treat HPV Related Cancers | 21MA047N |
| p53: Combination Therapy of Hypothermia and Chemotherapy to Treat Temperature Sensitive p53 Mutant Tumors | 21MA021N |
| BRD4 JAK2: Sultam (cyclic sulfonamide) BRD4 JAK2 Inhibitors to Treat Myelofibrosis | 21MA020N |
| TROLLS: Inhibition Of TAp63 Regulated Oncogenic Long Noncoding RNAs (TROLLs) for the Treatment Of Cancer | 20MB056 |
| β-Catenin/BCL-9: Acyl sulfonamide-containing Small Molecules that Inhibit the β-catenin/BCL9 Protein-Protein Interaction | 20MB051N |
| HPV E1: Novel Use for Aminocoumarins as HPV Helicase E1 Inhibitors to Treat Cancer | 20MB046 |
| CMG Helicase: Novel Replicative CMG Helicase Inhibitors (CMGi) to Treat Solid Tumors | 20MB046T2 |
| TAF1: Novel TAF1 Inhibitors for the Treatment of Cancer | 20MB037N |
| ACK1: Small molecule ACK1 Inhibitors for the Treatment of Castrate Resistant Prostate Cancer | 20MA015N |
| CDK12/CDK13: Novel Small Molecule Dual Inhibitors for CDK12/CDK13 for the Treatment of Triple Negative Breast Cancer | 19MB064N |
| β-catenin/BCL9: Novel Small Molecules that Inhibit the β-catenin/BCL9 Interaction in Breast Cancer | 19MB055 - VIDEO |
| Actinium Dotatate: Novel Atinum Dotatate Compounds with Low Toxicity and High Efficacy | 19MA018N |
| β-catenin/TCF: Small Molecule Peptidomimetic Inhibitors of the Interaction of β-catenin and T-cell Factor | 18MB076 |
| Novel BRD4/JAK2 Dual Inhibitor Cancer Therapeutics | 18MB053 |
| β-catenin/TCF: Small Molecule Inhibitors of the Interaction of β-catenin and T-cell Factor | 18MA018N |
| Ubiquitin Bispecific Antibody: Antibodies that Bring the E3 Ubiquitin Ligase into Close Proximity to Receptors to Induce the Receptor’s Degradation | 17MB056N |
| XBP-1: XBP-1 Inhibitor B-I09 for the Treatment of Acute GVHD and Solid Organ Rejection | 17MB051 |
| β-catenin/BCL-9: Small Molecules that Inhibit the β-catenin/BCL9 Interaction | 17MA014 |
| HDAC, BTK: Method of Using HDAC Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Chronic Lymphocytic Leukemia (CLL) | 16MA023N |
| Aurora/JAK2: Dual JAK2 and Aurora A Kinase Inhibitor for GVHD Prophylaxis | 16MA005N |
| Ras/Raf: Stapled Peptides as Inhibitors of Mutant KRAS | 15MA012 |
| Ras: Small Molecules that Inhibit Mutant KRAS | 15MA011 |
| WEE1: Small Molecule WEE1 Inhibitor (WEIN-159) that Inhibits WEE1 Phosphorylation of H2B but Not Cdc2 to Treat Can | 14MB092 |
| HDAC, BTK: Method of Using HDAC Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Non-Hodgkin’s Lymphoma (NHL) | 14MB086N |
| STAT3: Novel Small Molecule STAT3 Inhibitor for Cancer Treatment | 12MB098 |
| IRE-1: Novel Small Molecule Inhibitors of IRE-1 for the Treatment of B-cell Cancer | 12MB089 |
